Equity markets delivered a mixed response after Pfizer won the bidding war for anti-obesity drugmaker Metsera, as Metsera’s ...

Pfizer is working to deal with typical business issues in the drug space, but its attempt at a solution has become very ...

The first thing that comes to mind when we speak about the S&P 500 is the biggest tech companies, high valuations, and ...

Pfizer not only beat expectations last quarter, but also boosted its guidance.

US stocks rose Monday as Nvidia led tech gains, Apple delayed the iPhone Air, Pfizer acquired Metsera, and Trump unveiled a ...

Pfizer has won the week-long bidding war for Metsera with an upwardly revised up-to-$10 billion offer matching that of rival Novo Nordisk—and more than a little help from Washington.

Pfizer won its fight to buy obesity-drug maker Metsera, with an extra $1.7 billion and a little help from the Trump administration. Pfizer Inc. pulled off a comeback win, beating out Danish drug giant ...

The US drug giant beat Novo Nordisk in the $10 bln battle for biotech Metsera with the help of the Federal Trade Commission.

The new proposal for the coveted obesity drug developer is more than double the size of Pfizer’s original bid and ends a ...

Revised transaction values Metsera at up to $86.25 per share -- Metsera's Board of Directors unanimously recommends that Metsera stockholders approve the adoption of the amended Pfizer merger ...

While many of the top income stocks on the market are expensive, some can be had for well under $100 per share. Here are two ...

Compared to ABBV, PFE's latest dividend declarations and earnings report reveal growth pressure, high payout ratios, and ...